Total Payments
$18,669
2024 Payments
$8,508
Companies
12
Transactions
113
Medicare Patients
9,299
Medicare Billing
$7.4M
Payment Breakdown by Category
Food & Beverage$8,426 (45.1%)
Research$6,224 (33.3%)
Other$4,000 (21.4%)
Gifts$19.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,426 | 104 | 45.1% |
| Unspecified | $6,224 | 5 | 33.3% |
| Honoraria | $4,000 | 3 | 21.4% |
| Gift | $19.40 | 1 | 0.1% |
Payments by Type
General
$12,445
108 transactions
Research
$6,224
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alimera Sciences, Inc. | $17,216 | 55 | $0 (2024) |
| Genentech USA, Inc. | $491.88 | 24 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $359.03 | 13 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $160.89 | 7 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $126.01 | 2 | $0 (2024) |
| Aerie Pharmaceuticals, Inc. | $78.64 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $70.00 | 3 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $48.77 | 3 | $0 (2023) |
| Bausch & Lomb Americas Inc. | $45.13 | 2 | $0 (2023) |
| Boston Scientific Corporation | $40.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,508 | 19 | Alimera Sciences, Inc. ($8,296) |
| 2023 | $5,133 | 18 | Alimera Sciences, Inc. ($4,842) |
| 2022 | $3,043 | 10 | Alimera Sciences, Inc. ($2,991) |
| 2021 | $773.87 | 7 | Alimera Sciences, Inc. ($751.78) |
| 2020 | $186.73 | 11 | Novartis Pharmaceuticals Corporation ($87.86) |
| 2019 | $448.46 | 16 | Novartis Pharmaceuticals Corporation ($250.45) |
| 2018 | $315.96 | 17 | Genentech USA, Inc. ($143.26) |
| 2017 | $259.12 | 15 | Genentech USA, Inc. ($115.68) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/30/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $28.72 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/23/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Ophthalmology | ||||||
| 09/16/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/26/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $686.05 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/08/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: Ophthalmology | ||||||
| 06/24/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $662.20 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 06/21/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: General - Therapies_CRM | ||||||
| 05/13/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: Ophthalmology | ||||||
| 04/22/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $636.30 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/15/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Ophthalmology | ||||||
| 04/01/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/28/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $35.94 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 03/27/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $1,021.14 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 02/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/08/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $753.30 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 02/01/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $1,848.00 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 01/15/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $753.30 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 01/01/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | — | Cash or cash equivalent | $1,848.00 | Research |
| Study: Iluvien Study • Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 12/11/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $20.45 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/21/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/16/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Honoraria | Cash or cash equivalent | $1,200.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/02/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/25/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/05/2023 | Alimera Sciences, Inc. | YUTIQ (Drug) | Food and Beverage | Cash or cash equivalent | $608.25 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Iluvien Study | Alimera Sciences, Inc. | $6,224 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,404 | 32,376 | $4.6M | $1.7M |
| 2022 | 16 | 2,099 | 10,570 | $4.9M | $1.7M |
| 2021 | 15 | 2,264 | 8,328 | $5.4M | $2.0M |
| 2020 | 19 | 2,532 | 9,518 | $5.8M | $2.1M |
Total Patients
9,299
Total Services
60,792
Medicare Billing
$7.4M
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 90 | 26,220 | $2.0M | $763,522 | 38.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 95 | 728 | $1.5M | $501,319 | 34.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 249 | 1,118 | $302,771 | $97,046 | 32.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 24 | 414 | $249,300 | $75,490 | 30.3% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 16 | 315 | $123,480 | $49,881 | 40.4% |
| 92134 | Imaging of retina | Office | 2023 | 532 | 1,562 | $133,359 | $42,929 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 264 | 452 | $92,029 | $40,855 | 44.4% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 210 | 250 | $57,517 | $21,360 | 37.1% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 103 | 358 | $85,920 | $19,618 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 148 | 226 | $31,042 | $13,422 | 43.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 76 | 76 | $23,717 | $8,649 | 36.5% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 74 | 74 | $20,562 | $7,503 | 36.5% |
| 92250 | Photography of the retina | Office | 2023 | 283 | 291 | $36,126 | $6,584 | 18.2% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 11 | 13 | $15,600 | $3,341 | 21.4% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 88 | 128 | $6,127 | $2,334 | 38.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 128 | 128 | $3,822 | $1,492 | 39.0% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 13 | 23 | $4,094 | $722.12 | 17.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 123 | 1,410 | $2.8M | $1.0M | 35.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 44 | 1,208 | $724,800 | $269,261 | 37.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 240 | 1,210 | $287,684 | $108,190 | 37.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 31 | 3,150 | $415,472 | $93,161 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 239 | 527 | $106,454 | $47,261 | 44.4% |
| 92134 | Imaging of retina | Office | 2022 | 452 | 1,503 | $129,258 | $42,022 | 32.5% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 12 | 196 | $76,832 | $30,787 | 40.1% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 246 | 330 | $75,900 | $26,142 | 34.4% |
About Dr. Christopher Singh, MD
Dr. Christopher Singh, MD is a Ophthalmology healthcare provider based in Grand Blanc, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083724900.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Singh, MD has received a total of $18,669 in payments from pharmaceutical and medical device companies, with $8,508 received in 2024. These payments were reported across 113 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($8,426).
As a Medicare-enrolled provider, Singh has provided services to 9,299 Medicare beneficiaries, totaling 60,792 services with total Medicare billing of $7.4M. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Grand Blanc, MI
- Active Since 08/30/2006
- Last Updated 02/09/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1083724900
Products in Payments
- ILUVIEN (Drug) $14,036
- YUTIQ (Drug) $2,894
- Lucentis (Biological) $319.11
- Iluvien (Drug) $146.51
- BEOVU (Drug) $132.79
- Syfovre (Drug) $126.01
- Vabysmo (Drug) $98.60
- EYLEA (Biological) $82.40
- Rhopressa (Drug) $78.64
- Izervay (Drug) $70.00
- Iluvien (Biological) $54.56
- VABYSMO (Drug) $52.08
- XIPERE (Drug) $45.13
- EYLEA HD (Biological) $43.99
- EYLEA AFLIBERCEPT INJECTION (Biological) $34.50
- SUSVIMO (Drug) $22.09
- DUREZOL (Drug) $20.72
- None Specified (Medical Supply) $19.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Grand Blanc
Ankur Mehta, Md, MD
Ophthalmology — Payments: $13,529
Ophthalmology $13,529
Amy Zhang, Md, MD
Ophthalmology — Payments: $11,563
Ophthalmology $11,563
Dr. Raafay Sophie, Md, MD
Ophthalmology — Payments: $6,125
Ophthalmology $6,125
Dr. Charles Zenzen, Md, MD
Ophthalmology — Payments: $3,189
Ophthalmology $3,189
Christopher Herzog, D.o, D.O
Ophthalmology — Payments: $172.03
Ophthalmology $172.03